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Prescription patterns for diabetes 
mellitus and therapeutic implications: 
a population-based analysis
Padrões de prescrição e implicações terapêuticas para 
o diabetes melito: análise de base populacional
Camilo Molino Guidoni1, Anna Paula de Sá Borges1, 
Osvaldo de Freitas1, Leonardo Régis Leira Pereira1
ABSTRACT
Objective: To analyze drug prescriptions for insulin and oral antidiabetic drugs in type 1 and 
type 2 diabetes mellitus patients seen in the Brazilian Public Healthcare System (Unified Health 
System – SUS) in Ribeirao Preto, SP, Brazil. Subjects and methods: All the patients with dia-
betes seen in the SUS in the western district of Ribeirao Preto, SP, Brazil between March/2006 
and February/2007 were included in the study. Results: A total of 3,982 patients were identified. 
Mean age of the patients was 60.6 years, and 61.0% were females. Sixty percent of the patients 
were treated with monotherapy. Doses of oral antidiabetic drugs were lower in monotherapy 
than in polytherapy. Ten patients received doses of glibenclamide or metformin above the re-
commended maximum doses, and in elderly patients there was no reduction in drug doses. 
Conclusion: Monotherapy with oral antidiabetic drugs was the predominant procedure, and the 
doses were not individualized according to age. Arq Bras Endocrinol Metab. 2012;56(2):120-7
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RESUMO
Objetivo: Analisar as prescrições medicamentosas dos antidiabéticos orais e insulina em pa-
cientes portadores de diabetes melito tipo 1 e tipo 2 atendidos pelo Sistema Único de Saúde 
(SUS) em Ribeirão Preto, SP, Brasil. Sujeitos e métodos: Todos os pacientes com diabetes 
atendidos no distrito sanitário oeste de Ribeirão Preto, SP, do SUS, entre março/2006 e feve-
reiro/2007, foram incluídos no estudo. Resultados: Foram identificados 3.982 pacientes com 
diabetes. Idade média dos pacientes foi de 60,6 anos e 61,0% do gênero feminino. Sessenta por 
cento foram tratados com monoterapia. A dose dos antidiabéticos foi menor em monoterapia 
quando comparada à politerapia. Dez pacientes receberam doses de glibenclamida e metformi-
na acima da dose máxima recomendada. Além disso, em pacientes idosos, não houve redução 
da dose. Conclusão: A monoterapia com antidiabéticos orais foi prevalente e não houve indivi-
dualização da dose de acordo com a faixa etária. Arq Bras Endocrinol Metab. 2012;56(2):120-7
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INTRODUCTION
Diabetes mellitus (DM), a chronic non-transmissi-ble disease, is one of the most prevalent diseases 
in the world. According to the International Diabetes 
Federation, 6.6% of the worldwide adult population, 
and 6.0% of the Brazilian adult population had DM in 
2010. It is estimated that by 2030, approximately 7.8% 
of the worldwide adult population will have DM (1).
Concerning DM treatment, it is important to em-
phasize that non-pharmacological treatment is essential 
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in the care of the disease. However, if non-pharmaco-
logical treatment does not lead to acceptable glycemic 
control, patients should receive oral antidiabetic drugs 
(OAD), or insulin, or both. In Brazil, the two pharma-
cologic classes of OAD available in the National List of 
Essential Medicines for DM treatment are biguanide 
(metformin), and sulfonylurea (glibenclamide and glicla-
zide), as well as the hormone insulin (2). The increasing 
number of subjects diagnosed with the disease suggests 
that it is necessary to study and understand the profile of 
OAD and insulin use. In addition, in a previous study in 
Brazil, the greatest part of direct costs of DM treatment 
was attributed to medication (48.2%) (3). 
In the current context, pharmacoepidemiological stu-
dies are necessary and may be carried out using the com-
puterized drug monitoring systems. Thus, it may possible 
to describe drug use patterns, analyze early signals of the 
irrational drug use, promote interventions to improve 
drug use, analyze quality control cycles, and promote 
continuous quality improvement (4-7).
Moreover, these studies are highly relevant in Brazil. 
According to the Ministry of Health, 80.0% of the Brazi-
lian population use only the Brazilian Public Health Sys-
tem for their healthcare (8). Therefore, this study aimed 
at analyzing drug prescriptions for OAD and insulin in pa-
tients with DM types 1 and 2 seen in the Brazilian Uni-
fied Health System (SUS) of Ribeirao Preto, SP, Brazil.
SUBJECTS AND METHODS
Settings 
Based on the SUS guidelines, the municipal health 
office of Ribeirao Preto, SP, divided the city into five 
heal thcare districts: north, south, east, west and central, 
within which its 550,000 inhabitants were distributed 
in 2007. The five districts are meant to ensure that 
both primary and emergency care are close to people’s 
homes. This study was carried out in the western dis-
trict, which comprises a population of approximately 
140,000 inhabitants and 8 healthcare units.
Subjects
All patients with DM types 1 and 2 used in the study 
were seen in the western district of Ribeirao Preto, SP. 
They were selected from the district database, and all pa-
tients who received at least one of the OADs (gliben-
clamide 5 mg; metformin 850 mg; gliclazide 80 mg) or 
insulin from March 2006 and February 2007 were inclu-
ded. There were 3,918 patients with DM types 1 or 2. 
Patients with DM type 2 who received prescriptions for 
gliclazide (26 patients) were not included in the statistical 
analysis due to the small size of group, and the total num-
ber of patients was reduced to 3,892.
Data source
The municipal health office of Ribeirao Preto, SP, has 
a computer database that includes all the information 
on medical prescriptions issued by the SUS in the city 
of Ribeirao Preto, SP. Information in this database 
includes patient identification, gender, age, generic 
drug prescribed, drug dispensing date, dose regimen, 
amount of drug dispensed, and the health unit whe-
re the drug was dispensed. Database information was 
updated simultaneously with patient care.
Drugs were dispensed monthly by the healthcare unit 
pharmacies upon presentation of a prescription, and were 
simultaneously recorded in the database. All the drugs on 
the National List of Essential Medicines are dispensed free 
of charge by the SUS (2). All the necessary information 
was collected from the database of a single pharmacist.
Data analysis
The Anatomical Therapeutic Chemical Classification 
System with Defined Daily Doses (ATC/DDD)
The ATC/DDD is a system used to classify therapeutic 
drugs. It was used to stratify patients with DM into 
therapeutic groups according to the drug or drug com-
bination prescribed: insulin, glibenclamide, metformin, 
metformin plus glibenclamide, glibenclamide plus insu-
lin, metformin plus insulin, and metformin plus gliben-
clamide plus insulin. In addition, doses of glibenclami-
de, metformin and insulin were also analyzed using the 
ATC/DDD system, especially to define consumption 
doses (DDD per 1,000 inhabitants per day) (9).
Analysis of drug dose for the treatment of diabetes 
mellitus
Drug prescriptions were evaluated for each month of 
the study. It was possible to analyze insulin and OAD 
doses according to age and therapeutic group. Dose 
regimen for oral antidiabetic drugs and insulin in the 
treatment of DM has been well established using a 
number of individual dosing studies and analyses of the 
worldwide clinical database. 
In the treatment with metformin, the usual starting 
dose is 500 mg orally twice a day, or 850 mg orally once 
a day. To get to the maintenance dose, doses should be 
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increased by 500 mg weekly or 850 mg every two weeks 
for patients who do not show adequate therapeutic res-
ponse. The therapeutic dose range is from 1 to 2.55 g 
orally a day, divided into two to three doses, usually 
administered after the main meals (10,11).
In the treatment with glibenclamide, the usual star-
ting dose is 2.5-5.0 mg daily. The dose is usually increa-
sed by 2.5 milligrams at weekly intervals, depending on 
the patient’s response. The therapeutic dose range is from 
1.25 to 20.0 mg a day, which may be given as single or 
multiple doses, usually before the main meals (10,12).
In the treatment with insulin, the dose is individuali-
zed according to the patient’s needs. The average dose 
per patient with DM ranges from 0.7 to 1.5 U/kg/
day. Obese patients may require doses of 2.0 U/kg/
day due to insulin resistance. In the association of insu-
lin with OAD, patients should continue taking OAD in 
the same dose (possibly reduced), administering insulin 
in a single dose at bedtime (starting with about 10.0 
to 15.0U, or 0.2 U/kg in obese patients). The insulin 
dose is adjusted using 2.0, 4.0, or 6.0U (if capillary 
blood glucose level is consistently higher than 120, 140 
or 160 mg/dL, respectively), every three days until tar-
get fasting plasma glucose level is reached (13,14).
Analysis of variation in dose and number of drugs 
used for diabetes mellitus treatment
As described above, drug prescriptions were evaluated 
for each month of the study. OAD and insulin doses 
were analyzed per patient to observe in which patients 
the doses were decreased, increased or maintained du-
ring the period. Furthermore, it was possible to analyze 
the number of drugs used for the DM treatment, clas-
sifying treatment as monotherapy or polytherapy and, 
at the end of the study, it was possible to examine in 
which patients the number of drugs prescribed for the 
treatment of DM was modified, and if changes were 
classified as simple addition (combination with another 
drug), addition by substitution (replacement with ano-
ther drug), or drug withdrawal.
Ethics committee approval
This study was approved by the Research Ethics Com-
mittee of the Health Training Center at the School of 
Medicine of Ribeirao Preto, SP, Universidade de Sao 
Paulo, Brazil.
Statistical analysis
The statistical package for Social Sciences® (SPSS, ver-
sion 11.5, 2002) and Microsoft Excel® (Microsoft Cor-
poration, 2007) were used to record and analyze data. 
ANOVA was used to test the differences between the 
means of continuous variables with Gaussian distribution, 
and statistical significance was considered when p < 0.05.
RESULTS 
There were 3,918 patients identified with DM types 1 
or 2. After excluding patients to whom gliclazide was 
prescribed (26 patients), 3,892 patients were analyzed. 
There was a large proportion (55.0%) of elderly (≥ 60 
years) individuals with mean age of 60.6 (± 13.2), and a 
higher proportion of females (61.0%).
Table 1 shows the Anatomical Therapeutic Chemical 
groups of this study in relation to the number of DM 
patients, their mean age, minimum and maximum ages.
Table 1. Age group profile and number of patients with diabetes mellitus in each Anatomical Therapeutic Chemical group
Anatomical Therapeutic Chemical groups n = 3,892 (%)
Age (years)
Mean (SD) Minimum Maximum
Monotherapy Insulin 131 (3.4) 51.2 (20.3)a 07 93
Glibenclamide 959 (24.6) 64.1 (12.5)b 18 96
Metformin 1,245 (32.0) 57.7 (13.5)a 14 96
Polytherapy Metformin plus glibenclamide 1,112 (28.6) 61.3 (11.6) 23 92
Glibenclamide plus insulin 60 (1.5) 64.2 (10.7) 40 90
Metformin plus insulin 267 (6.9) 61.6 (12.1) 13 90
Metformin plus glibenclamide plus insulin 118 (3.0) 60.6 (11.3) 27 85
Total 3,892 60.6 (13.2) 07 96
a p < 0.05 when compared with all Anatomical Therapeutic Chemical groups. 
b p < 0.05 when compared with metformin, and metformin plus glibenclamide groups.
SD: standard deviation.
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Box 1 shows therapeutic profiles of the patients with 
DM types 1 and 2 correlated with the age group and the 
respective mean dosages of metformin, glibenclamide, 
and insulin.
Figure 1 shows total consumption of defined daily 
doses per 1,000 inhabitants per day (DDD/1,000 inha-
bitants/day) of OAD and insulin. 
Glibenclamide and metformin were prescribed to 
four and six patients at doses above 20.0 mg/day and 
2,550 mg/day, respectively. In addition, metformin 
was prescribed to other 128 patients at a dose below 
500 mg/day.
At the end of the study, it was possible to analyze in 
which patients the number of drugs prescribed was chan-
ged. There were 11.7% of changes in the therapeutic regi-
men of glibenclamide, and changes were simple addition 
(5.2%), addition by substitution (2.8%), and glibenclami-
de withdrawal (3.7%). With respect to metformin, there 
were 11.2% of changes in the therapeutic regimen, and 
changes were simple addition (6.0%), addition by substi-
tution (2.1%), and metformin withdrawal (3.1%). For in-
sulin, there were 18.4% modifications in the therapeutic re-
gimen, and changes were simple addition (9.8%), addition 
by substitution (6.4%), and insulin withdrawal (2.2%).
Changes in OAD and insulin doses were analyzed 
during the period studied. Approximately 15.3%, 
18.2%, and 13.3% of the patients receiving glibenclami-
de, metformin and insulin, respectively, had their doses 
increased. In addition, 4.7%, 3.4% and 10.9% of the pa-
tients receiving glibenclamide, metformin, and insulin, 
respectively, had their doses reduced.
DISCUSSION 
In the present study, 60.0% of the patients identified 
were treated with only one drug, demonstrating a pre-
valence of monotherapy. Previous reports in the litera-
ture cited by Vauzelle-Kervröedan and cols., Bosi and 
cols., and Baviera and cols., also indicated a prevalen-
ce of monotherapy in 69.6%, 61.8% and 51.5% of the 
patients, respectively (15-17). However, in Colombia, 
Alba and cols. observed that polytherapy was more fre-
quent, since 52.0% of the patients used a combination 
of OADs (18). 
In the present study, 32.0% and 24.6% of the pa-
tients used metformin and glibenclamide, respectively, 
in monotherapy (Table 1). Other reports in the litera-
ture indicated values of 25.1%, 17.6%, and 32.8% for 
monotherapy with metformin, and 44.5%, 20.0%, and 
18.9% for sulfonylurea (15,18,19). These results illus-
trate differences in OAD prescriptions. Indeed, bigua-
nides and sulfonylurea are first-choice treatments, whi-
le metformin is mainly indicated for obese and insulin 
resistance patients, and glibenclamide is mainly used in 
patients with a normal body mass (13,20,21).
Gliclazide, another OAD available on the National 
List of Essential Medicines, was little prescribed in ei-
ther monotherapy or polytherapy. The use of glicazide 
in the SUS is restricted to elderly patients. This OAD 
was only prescribed to 26 patients, and five of them 
used it in an inappropriate combination with glibencla-
mide. According to the Brazilian Society of Diabetes 
and the American Diabetes Association, when a com-
bination of two or three OADs is required in the treat-
ment of DM, agents from different classes should be 
used (13,20,22).
Since glibenclamide, gliclazide, and metformin are 
the only OADs available in the SUS, therapeutic op-
tions are limited. This probably explains the rather high 
number of individuals using monotherapy with gliben-
clamide or metformin. Another monotherapy identi-
fied in the study was insulin, but its use was discrete 
(3.4%) when compared to the other therapies. 
Generally, doses used in OAD monotherapy are 
reduced, to prevent or control adverse side effects, 
and these doses are changed or not according to the 
patient’s response to the treatment. A retrospective stu-
dy demonstrated that patients with DM type 2 treated 
with metformin or sulfonylurea monotherapy did not 
need additional treatment for 14.5 to 20.5 months, 
respectively, and, after these periods, glycosylated he-
moglobin (HbA1c) exceeded 8.0% for both therapeu-
tic options. DM is a progressive disease that can cause 
deterioration of glycemic control (glucose toxicity), 
making it necessary to change pharmacotherapy with 
time (23,24).
There were no statistical differences in the dose 
versus age group in patients treated with metformin or 
glibenclamide in monotherapy (Box 1A and 1B). Des-
pite the fact that the authors did not have access to 
appropriate clinical information to verify the need to 
change the dose, reductions in the sulfonylurea dosages 
have been recommended in elderly patients, especially 
for OAD showing long elimination half-lives, such as 
glibenclamide, because of increased risks of adverse 
reac tions such as hypoglycemia (25). In addition, some 
authors warn against the use of metformin in elderly 
patients due to an increasing risk of lactic acidosis (20).
Prescription patterns for diabetes mellitus
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Box 1. Profile of the therapeutic prescriptions of metformin (A), glibenclamide (B) and insulin (C) for patients with diabetes mellitus according to the 
Anatomical Therapeutic Chemical group and age
A. Profile of the therapeutic prescriptions of metformin for patients with diabetes mellitus type 2 according to their Anatomical Therapeutic Chemical 
group and age
Age Group
Anatomical Therapeutic Chemical groups
Metformin
Mean dose (mg) (SD)
Glibenclamide plus metformin
Mean dose (mg) (SD)
Metformin plus insulin
Mean dose (mg) (SD)
Glibenclamide plus metformin 
plus insulin
Mean dose (mg) (SD)
< 40 1,446 (593)b 1,853 (683) 2,401 (318)e 1,643 (927)
40-49 1,520 (642)a 1,945 (565) 1,744 (588) 1,654 (708)
50-59 1,429 (639)c 1,917 (631) 1,884 (638) 2,108 (621)
60-69 1,395 (637)c 1,843 (609) 1,858 (591) 1,936 (608)
70-79 1,452 (605)b 1,743 (643)d 1,781 (691) 1,720 (761)
> 80 1,353 (504)a 1,761 (648) 1,438 (556) 1,700 (694)
a p < 0.05 when compared with the glibenclamide plus metformin group.
b p < 0.05 when compared with the glibenclamide plus metformin, and metformin plus insulin groups.
c p < 0.05 when compared with the Anatomical Therapeutic Chemical groups.
d p < 0.05 when compared with the 40-49 and 60-69 age group.
e p < 0.05 when compared with 70-79 and > 80 age groups.
SD: standard deviation.
B. Profile of the therapeutic prescriptions of glibenclamide for patients with diabetes mellitus type 2 according to their Anatomical Therapeutic 
Chemical group and age
Age group
Anatomical Therapeutic Chemical groups
Glibenclamide
Mean dose (mg) (SD)
Glibenclamide plus metformin
Mean dose (mg) (SD)
Glibenclamide plus insulin
Mean dose (mg) (SD)
Glibenclamide plus metformin 
plus insulin
Mean dose (mg) (SD)
< 40 8.6 (4.0)a 11.7 (5.0) - 12.5 (3.5)
40-49 8.3 (4.0)b 11.9 (4.4) 10.8 (4.9) 12.6 (5.8)
50-59 9.1 (4.1)b 11.6 (4.4) 12.2 (4.9) 13.1 (3.2)
60-69 8.8 (4.2)c 11.9 (4.1) 13.5 (3.8) 12.9 (4.1)
70-79 8.5 (4.0)c 11.9 (3.9) 11.4 (4.6) 11.3 (4.6)
> 80 7.7 (4.0)b 11.2 (4.3) 5.0 (0.0) 13.8 (4.8)
a p < 0.05 when compared with the glibenclamide plus metformin group.
b p < 0.05 when compared with glibenclamide plus metformin, and glibenclamide plus metformin plus insulin groups.
c p < 0.05 when compared with all Anatomical Therapeutic Chemical groups.
SD: standard deviation.
C. Profile of the therapeutic prescriptions of insulin for patients with diabetes mellitus type 1 or type 2 according to their Anatomical Therapeutic 
Chemical group and age
Age group
Anatomical Therapeutic Chemical groups
Insulin
Mean dose (UI) (SD)
Metformin plus insulin
Mean dose (UI) (SD)
Glibenclamide plus insulin
Mean dose (UI) (SD)
Glibenclamide plus metformin 
plus insulin
Mean dose (UI) (SD)
< 40 54.0 (24.0) 48.0 (32.0) - 33.0 (22.0)
40-49 46.0 (18.0) 53.0 (30.0) 17.0 (14.0)a,f 36.0 (24.0)
50-59 63.0 (40.0) 52.0 (32.0) 48.0 (31.0) 29.0 (18.0)b
60-69 53.0 (24.0)d 55.0 (29.0)d 29.0 (14.0) 28.0 (17.0)
70-79 67.0 (49.0)c 47.0 (25.0)e 31.0 (17.0) 28.0 (16.0)
> 80 41.0 (15.0) 42.0 (19.0) 25.0 (11.0) 24.0 (7.0)
a < 0.05 when compared to the metformin plus insulin group.
b p < 0.05 when compared to the insulin and metformin plus insulin groups. 
c p < 0.05 when compared to all Anatomical Therapeutic Chemical groups.
d p < 0.05 when compared to the glibenclamide plus Insulin and glibenclamide plus metformin plus insulin groups.
e p < 0.05 when compared to the glibenclamide plus metformin plus insulin group.
f p < 0.05 when compared to the 50-59 age group.
SD: standard deviation.
Prescription patterns for diabetes mellitus
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From the patients selected in this investigation, 
28.6% used a combination of metformin plus glibencla-
mide. Other studies reported values of 28.4%, 39.0%, 
and 14.5% for the combination of metformin plus sul-
fonylurea (15,18,19). A United Kingdom Prospective 
Study demonstrated that the combination of these drugs 
improved the levels of HbA1c over a three-year period 
(23). In another study, the combination of metformin 
plus glibenclamide reduced the levels of HbA1c to less 
than 6.0% in 40.0% of the patients, while monotherapy 
with metformin or glibenclamide produced the same 
results only in 10.0% and 17.0% of the subjects using 
this treatment, respectively (26). 
The dosages of OAD were lower in monotherapy 
when compared with those prescribed in polytherapy 
(Box 1A and 1B). When glycemic control is not pos-
sible, another OAD should be added, provided that 
the first one was used in the maximum recommended 
dose, indicating dose optimization (13,21). However, 
this was not obvious in the database since the doses of 
metformin and glibenclamide were far from optimum 
when the second OAD was added. This may be par-
tially explained if one considers that patients with DM 
type 2 show different pathological mechanisms, war-
ranting an early introduction of polytherapy, or when 
drug optimization is carried out according to patient 
tolerance. 
The third step in the treatment of patients with un-
controlled DM type 2 would be the introduction of a 
third OAD or insulin (13,20,21). The only option for 
SUS patients is to receive insulin, because the system 
does not have a third standardized class of OAD. In this 
instance, the practitioner may decide to add the hor-
mone, or choose complete insulinization. The Colla-
borative Drug Therapy Management Service showed 
that the introduction of insulin or dose adjustment in 
patients with DM type 2 improves glycemic control in 
patients with HbA1c levels over 9.0% (27). However, 
in these cases, the introduction of insulin is less fre-
quent than recommended, and usually started late in 
the course of the disease. This treatment is invasive and 
painful, and frequently negatively affects the patient-
-physician relationship and, consequently, the physician 
is reluctant to start it. Other concerns are also involved, 
since physicians, patients and families worry about the 
side effects, such hypoglycemia and weight gain, spe-
cially in elderly patients (13,28-30).
Insulin polytherapy was used to treat 11.4% of the 
patients identified (Table 1), and an appreciable pro-
portion of subjects required close attention in relation 
to glycemic control in a treatment considered to be 
more aggressive. Note that the database used in the 
present study did not provide laboratory results. Accor-
ding to the Brazilian Society of Diabetes, the combina-
tion of a biguanide or sulfonylurea agent with insulin 
contributes to reducing hormone doses, facilitating the 
transition to full insulin treatment, besides increasing 
treatment acceptance and compliance (13). Other stu-
dies also reported reduction in insulin doses in patients 
treated with metformin (31,32). In the present study, 
6.9% of the patients were treated with metformin and 
insulin (Table 1). However, recent data have shown 
favorable outcomes related to the recovery and main-
tenance of b-cell function and protracted glycemic re-
mission in newly diagnosed patients with DM type 2, 
which made therapy with OAD plus insulin comparable 
with OAD alone (20,24).
Concerning insulin doses, they were higher in the 
monotherapy group than the polytherapy group, with 
the exception of the combination metformin plus in-
sulin. In general, patients with DM types 1 or 2 in ad-
vanced stages require full insulinization with high doses 
(13,21). A reduction in insulin levels was not seen in 
the combination metformin plus insulin, when compa-
red with glibenclamide plus insulin. The reduction in 
insulin doses when the hormone was combined with 
glibenclamide was statistically significant in the 40-79 
age group (Box 1C). It is known that glibenclamide 
aids insulin secretion by pancreatic b-cells, and this fac-
tor may be related with a reduction in insulin doses.
Figure 1. Use of oral antidiabetic drugs and insulin in defined daily doses 
per 1,000 inhabitants per day (DDD/1,000 inhabitants/day).
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The use of OAD and insulin during the period stu-
died was 14.5, 11.5, and 13.2 DDD/1,000 inhabitants/
day for glibenclamide, metformin and insulin, respective-
ly (Figure 1). A study carried out in 2003 in 10 European 
countries found variations in the use of sulfonylurea from 
9.0 to 24.5 DDD, metformin from 5.5 to 14.0 DDD, 
and insulin from 6.5 to 23.0 DDD (33). In relation to 
changes in the number of drugs used, a second or third 
drug was added to 14.0% of the patients treated. In addi-
tion, approximately a quarter of the patients had their 
OAD and insulin doses modified, with greater prevalence 
for increased doses. Boccuzzi and cols. found increased 
doses in 30.7% and 23.6% for patients using metformin 
and glibenclamide, respectively (34).
 In addition, 3.5% of the prescriptions showed errors 
in the OAD recommended doses, 10 of which had high 
doses of metformin and glibenclamide, and 128 had low 
doses of metformin. These findings have clinical relevan-
ce, since they represent evidence of a risk of toxicity or 
ineffectiveness of the therapy.
There were some limitations in the present study sin-
ce the database did not provide clinical diagnoses or labo-
ratory results. However, the study does have its strengths. 
Methodology used was fast and low-cost, which made it 
easy to manage a large number of patients. The study was 
developed in a district with 140,000 inhabitants, a popu-
lation size representative of hundreds of Brazilian cities. 
Computer databases are also low-cost systems, enabling 
management and analysis of drug use at the municipal, 
state and federal levels. It is unfortunate that the system 
has limited use in countries like Brazil, being only used in 
drug purchase and control of drug inventories. However, 
a computer system known as HORUS was developed in 
2009 by the Department of Pharmaceutical Assistance of 
the Brazilian Ministry of Health, the first countrywide 
system aiming at improving drug management, intensi-
fying actions related to drug use and rational use.
CONCLUSIONS
OAD monotherapy was the predominant treatment for 
DM in this study. The doses used in monotherapy were 
lower than those used in polytherapy. There was no in-
dividualization of doses according to age group, par-
ticularly in elderly patients. It was possible to estimate 
the use of OAD and insulin that may contribute to im-
proving issues related to drug management. Therefore, 
the database enabled the analysis of drug therapy, drug 
doses, drug management, and prescription failures 
being valuable tools for the pharmacist to investigate 
prescription profiles, contributing to patient care. 
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